Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Mitsugu Sekimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2184-538X; OpenAlex author ID A5043799958. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 4 papers · 2023: 6 papers · 2024: 1 paper · 2025: 1 paper

Papers 24

  1. Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal… Last author DOI 10.1245/s10434-024-16361-y↗
  2. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clini… Co-author DOI 10.1016/j.pan.2024.03.012↗
  3. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. Last author DOI 10.1002/ags3.12608↗
  4. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal aden… Last author DOI 10.1016/j.pan.2022.11.012↗
  5. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.04.001↗
  6. Efficacy of Lentinula edodes Mycelia Extract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients. Last author DOI 10.1080/01635581.2022.2107226↗
  7. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  8. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospectiv… Last author DOI 10.21037/jgo-23-655↗
  9. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jhbp.1026↗
  10. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Last author DOI 10.1186/s13063-021-05934-x↗
  11. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  12. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Last author DOI 10.3390/cancers14051354↗
  13. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therap… Last author DOI 10.1007/s00595-021-02308-3↗
  14. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  15. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  16. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12295↗
  17. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  18. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00595-020-01963-2↗
  19. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers12061428↗
  20. [A Case of Long-Term Survival after Total Pancreatectomy for Recurrent Pancreatic Cancer in the Remnant Pancreas after Pancreatoduodenectomy]. Co-author PMID 30914550↗
  21. Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemothe… Co-author DOI 10.1007/s13691-017-0311-0↗
  22. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis. Co-author DOI 10.1016/j.hbpd.2018.01.004↗
  23. A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer pat… Last author DOI 10.1136/bmjgast-2017-000187↗
  24. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.006↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. So Yamaki · 17 shared papers, 2020–2025 · strength 2.58
  2. Tomohisa Yamamoto · 17 shared papers, 2020–2024 · strength 2.50
  3. Sohei Satoi · 17 shared papers, 2020–2025 · strength 2.48
  4. Daisuke Hashimoto · 13 shared papers, 2021–2025 · strength 1.99
  5. Tsukasa Ikeura · 7 shared papers, 2022–2025 · strength 1.18
  6. Satoshi Hirooka · 6 shared papers, 2020–2023 · strength 0.94
  7. Yuki Matsui · 5 shared papers, 2022–2025 · strength 0.89
  8. Tatsuma Sakaguchi · 6 shared papers, 2020–2023 · strength 0.85
  9. Suguru Yamada · 4 shared papers, 2020–2024 · strength 0.54
  10. Yasuhiro Kodera · 4 shared papers, 2020–2022 · strength 0.45
  11. Satoshi Hirano · 4 shared papers, 2020–2022 · strength 0.45
  12. Tsutomu Fujii · 4 shared papers, 2020–2022 · strength 0.45
  13. Denys Tsybulskyi · 2 shared papers, 2023–2025 · strength 0.40
  14. Hironori Ryota · 3 shared papers, 2020–2021 · strength 0.35
  15. Hiroaki Yanagimoto · 2 shared papers, 2020–2023 · strength 0.35
  16. Joji Kitayama · 3 shared papers, 2020–2022 · strength 0.31
  17. Fuyuhiko Motoi · 3 shared papers, 2020–2022 · strength 0.31
  18. Shoji Nakamori · 4 shared papers, 2016–2019 · strength 0.30
  19. Atsushi Miyamoto · 4 shared papers, 2016–2019 · strength 0.30
  20. Koh Nakamaru · 2 shared papers, 2022–2023 · strength 0.27
  21. Kenichiro Uemura · 2 shared papers, 2022 · strength 0.26
  22. Masashi Kanai · 1 shared paper, 2025 · strength 0.22
  23. Hidetaka Miyazaki · 1 shared paper, 2025 · strength 0.22
  24. Hiroshi Ishii · 2 shared papers, 2018–2023 · strength 0.22
  25. Makoto Ueno · 2 shared papers, 2018–2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.